With inflation concerns linked to higher energy prices, mixed signals on global growth, and bond yields reacting to every new policy hint, many investors are looking for companies where earnings expectations and balance sheet strength are clearly spelled out. That is exactly what the Healthy high growth potential screener focuses on. It highlights stocks where analysts forecast solid earnings growth over the next 3 years and financial positions that pass basic quality checks. This article introduces three of the best stocks from that screener, helping you narrow a crowded market down to a focused list of ideas to research further.

Intellia Therapeutics (NTLA)

Overview: Intellia Therapeutics is a clinical-stage biotech company developing CRISPR/Cas9 gene-editing treatments that aim to correct disease at its genetic source, with a pipeline that includes in vivo therapies for transthyretin amyloidosis, hereditary angioedema and several immuno-oncology and autoimmune conditions, supported by multiple partnerships with larger drug developers.

Operations: Intellia currently generates US$66.1 million in revenue from the development of gene editing based therapies, all from the United States.

Market Cap: US$1.6b

Investors interested in high growth healthcare may pay attention to Intellia Therapeutics because it is active in in vivo CRISPR, with late stage data in hereditary angioedema already published in NEJM and a rolling FDA filing underway. The company is still loss making with ongoing cash burn, relies on a concentrated pipeline and faces competition from other genetic medicines. Outcomes will depend heavily on trial results, regulatory decisions and eventual reimbursement, and these factors shape both the potential opportunities and the major pressure points for the business.

Intellia Therapeutics sits at the crossroads of cutting edge gene editing and high execution risk, so it helps to see how analysts connect the science to potential returns in the analyst forecasts for Intellia Therapeutics and what might upend that story next.

Insulet (PODD)

Overview: Insulet develops and sells the Omnipod family of wearable insulin delivery systems, including the automated Omnipod 5, which pairs with continuous glucose monitors to adjust insulin in real time for people with insulin dependent diabetes in the United States and internationally, as well as drug delivery pods for partners such as Amgen.

Operations: Insulet generates US$2.9b in revenue from drug delivery systems, with about US$2.1b from the United States and US$844.9m from international markets.

Market Cap: US$11.4b

Insulet attracts attention because Omnipod 5 is gaining ground in a large and underpenetrated type 2 diabetes market, supported by strong clinical data, expanding international rollouts and broad pharmacy and reimbursement access that point to recurring revenue from a growing user base. At the same time, heavy dependence on a single product platform, margin pressure after profit fell, and a series of product recalls and legal actions keep risk firmly on the table. The key consideration for investors is whether Omnipod’s ecosystem and future closed loop systems can sufficiently offset those operational and regulatory concerns.

Insulet’s Omnipod growth story is accelerating, but the recalls, profit pressure and legal overhang leave key questions unanswered, so it is worth reviewing the 2 key rewards and 1 important warning sign

Hamilton Lane (HLNE)

Overview: Hamilton Lane is a Philadelphia based private markets specialist that manages private equity and credit funds, evergreen products and customized portfolios for institutions and wealth clients, giving investors access to buyouts, growth equity, venture capital and other alternative strategies around the world.

Operations: Hamilton Lane generates US$759.0 million in asset management revenue, with about US$310.4 million from the United States and US$448.6 million from other countries.

Market Cap: US$4.8b

Hamilton Lane stands out in the Healthy high growth potential screener because it combines a global private markets platform with strong fee based economics and a deep pipeline of evergreen and specialized funds that feed recurring asset management revenue. Earnings and revenue are both forecast to grow solidly, supported by high fee earning assets, a growing technology and data offering and long term client relationships. A P/E below the broader US Capital Markets industry and a Simply Wall St DCF estimate well above the current share price suggest investors are not paying a premium for that profile. The flip side is clear. Heavier regulation, fee pressure, reliance on external funding and one off gains can all affect how durable those earnings really are, which is where deeper analysis becomes essential.

Hamilton Lane’s fee power and P/E gap hint that investors may be missing something in this private markets story, and the 4 key rewards and 1 important warning sign could reveal the twist that ties it all together

The three stocks in this article are only a small sample, and the full Healthy high growth potential screener surfaces 1,510 more companies with equally compelling growth and balance sheet stories through the Healthy high growth potential screener. Use Simply Wall St to identify, filter and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction opportunities.

Take Control of Your Investment Journey

If Hamilton Lane or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

New breakout trends rarely stay under the radar for long. Spot fresh momentum stocks and sectors before the crowd catches on, while the data still matters. Act now.

• Target resilient cash generators by scanning a curated list of solid balance sheet and fundamentals (48 results) so you are not caught holding fragile businesses when conditions turn.
• Chase quality income opportunities with a hand picked 9 dividend fortresses that aims to combine robust balance sheets with income streams investors often overlook.
• Ride the next wave of automation by reviewing a focused 33 robotics and automation stocks packed with companies building the hardware and software behind rising productivity trends.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.